DB:BFF1

Stock Analysis Report

Executive Summary

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases.


Snowflake Analysis

Acceptable track record with weak fundamentals.

Share Price & News

How has Sophiris Bio's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BFF1's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.6%

BFF1

-2.3%

DE Biotechs

-0.2%

DE Market


1 Year Return

-33.0%

BFF1

8.4%

DE Biotechs

13.7%

DE Market

Return vs Industry: BFF1 underperformed the German Biotechs industry which returned 8.4% over the past year.

Return vs Market: BFF1 underperformed the German Market which returned 13.7% over the past year.


Shareholder returns

BFF1IndustryMarket
7 Day1.6%-2.3%-0.2%
30 Day-8.4%-3.2%0.3%
90 Day91.5%6.3%3.7%
1 Year-33.0%-33.0%8.6%8.4%17.2%13.7%
3 Year-72.7%-72.7%44.5%42.9%15.4%5.3%
5 Year69.3%69.3%13.0%10.6%21.3%4.7%

Price Volatility Vs. Market

How volatile is Sophiris Bio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sophiris Bio undervalued compared to its fair value and its price relative to the market?

586.33x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BFF1's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BFF1's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BFF1 is poor value based on its PE Ratio (586.3x) compared to the Biotechs industry average (39.7x).

PE vs Market: BFF1 is poor value based on its PE Ratio (586.3x) compared to the German market (20.9x).


Price to Earnings Growth Ratio

PEG Ratio: BFF1's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: BFF1 has negative assets, so we can't compare its PB Ratio to the DE Biotechs industry average.


Next Steps

Future Growth

How is Sophiris Bio forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-65.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BFF1's earnings are forecast to decline over the next 3 years (-65.7% per year).

Earnings vs Market: BFF1's earnings are forecast to decline over the next 3 years (-65.7% per year).

High Growth Earnings: BFF1's earnings are forecast to decline over the next 3 years.

Revenue vs Market: Insufficient data to determine if BFF1's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if BFF1's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BFF1's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Sophiris Bio performed over the past 5 years?

34.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BFF1 has high quality earnings.

Growing Profit Margin: BFF1 became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: BFF1 has become profitable over the past 5 years, growing earnings by 34.4% per year.

Accelerating Growth: BFF1 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: BFF1 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: BFF1's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Sophiris Bio's financial position?


Financial Position Analysis

Short Term Liabilities: BFF1 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: BFF1 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: BFF1 has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: BFF1's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: BFF1 has a low level of unsold assets or inventory.

Debt Coverage by Assets: BFF1 has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BFF1 is profitable, therefore cash runway is not a concern.

Forecast Cash Runway: BFF1 is profitable, therefore cash runway is not a concern.


Next Steps

Dividend

What is Sophiris Bio's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.7%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate BFF1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BFF1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BFF1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BFF1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BFF1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

9.9yrs

Average management tenure


CEO

Randy Woods (67yo)

7.5yrs

Tenure

US$774,526

Compensation

Mr. Randall E. Woods, also known as Randy, has been the Chief Executive Officer and President of Sophiris Bio, Inc. since August 16, 2012. Mr. Woods founded and served as the President and Chief Executive  ...


CEO Compensation Analysis

Compensation vs Market: Randy's total compensation ($USD774.53K) is above average for companies of similar size in the German market ($USD412.50K).

Compensation vs Earnings: Randy's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Randall Woods
President7.5yrsUS$774.53k0.080% $17.5k
Peter Slover
Chief Financial Officer7.1yrsUS$503.96k0.014% $3.0k
Samuel Denmeade
Chief Scientific Officer & Member of the Scientific Advisory Board0yrsno datano data
James Beesley
Senior Director of Investor Relations0yrsno datano data
Iain Mant
Corporate Secretary12.8yrsno datano data

9.9yrs

Average Tenure

47yo

Average Age

Experienced Management: BFF1's management team is seasoned and experienced (9.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Randall Woods
President7.5yrsUS$774.53k0.080% $17.5k
Samuel Denmeade
Chief Scientific Officer & Member of the Scientific Advisory Board0yrsno datano data
Gerald Proehl
Independent Director5.9yrsUS$118.84k0.029% $6.4k
Lars Ekman
Independent Chairman of the Board8.8yrsUS$142.84k0.0015% $330.5
John Geltosky
Independent Director11.4yrsUS$110.84kno data
Allison Hulme
Director3.3yrsUS$703.24kno data
Mark Emberton
Member of Scientific Advisory Board1.1yrsno datano data
Scott Eggener
Member of Scientific Advisory Board1.1yrsno datano data
Hashim Ahmed
Member of Scientific Advisory Board1.1yrsno datano data
Scott Coffield
Member of Scientific Advisory Board1.1yrsno datano data

3.3yrs

Average Tenure

67yo

Average Age

Experienced Board: BFF1's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sophiris Bio, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sophiris Bio, Inc.
  • Ticker: BFF1
  • Exchange: DB
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €21.890m
  • Shares outstanding: 34.47m
  • Website: https://www.sophirisbio.com

Number of Employees


Location

  • Sophiris Bio, Inc.
  • 1258 Prospect Street
  • La Jolla
  • California
  • 92037
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BFF1DB (Deutsche Boerse AG)YesCommon SharesDEEURAug 2003
SPHSNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDAug 2003

Biography

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company’s primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 21:41
End of Day Share Price2020/02/20 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.